Key clinical point: Janus kinase (JAK) inhibitors are an effective and safe treatment option for psoriatic arthritis (PsA).
Major finding: The American College of Rheumatology 20 response was significantly higher with JAK inhibitors vs placebo (odds ratio [OR], 3.78; 95% confidence interval [CI], 2.72-5.24). The risk for serious adverse events was not significantly higher with JAK inhibitors vs placebo (OR, 1.12; 95% CI, 0.14-2.82).
Study details: Findings are from a meta-analysis of 5 randomized controlled trials including 3,293 adult patients with PsA who were treated with JAK inhibitors or placebo.
Disclosures: The study did not report any source of funding. No conflict of interests was reported.
Source: Campanero F et al. Autoimmun Rev. 2021 Jul 15. doi: 10.1016/j.autrev.2021.102902 .